Intellia Therapeutics (NASDAQ:NTLA) Upgraded to Buy at ValuEngine

ValuEngine upgraded shares of Intellia Therapeutics (NASDAQ:NTLA) from a hold rating to a buy rating in a report issued on Thursday, ValuEngine reports.

NTLA has been the topic of several other reports. Zacks Investment Research downgraded shares of Intellia Therapeutics from a buy rating to a hold rating in a report on Wednesday, July 10th. Wedbush upgraded shares of Intellia Therapeutics from a neutral rating to an outperform rating and raised their price objective for the stock from $20.00 to $21.00 in a research report on Friday, May 3rd. Chardan Capital restated a buy rating and set a $57.50 price objective on shares of Intellia Therapeutics in a research report on Tuesday, May 28th. Roth Capital initiated coverage on shares of Intellia Therapeutics in a research report on Monday, June 10th. They set a neutral rating and a $16.00 price objective for the company. Finally, Evercore ISI initiated coverage on shares of Intellia Therapeutics in a research report on Thursday, April 11th. They set an outperform rating for the company. Seven equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. The company currently has a consensus rating of Buy and an average price target of $25.31.

NTLA traded down $0.48 during midday trading on Thursday, hitting $17.61. 539,821 shares of the company traded hands, compared to its average volume of 492,358. The company has a debt-to-equity ratio of 0.06, a current ratio of 7.74 and a quick ratio of 7.74. The stock has a market cap of $804.95 million, a P/E ratio of -8.89 and a beta of 2.62. Intellia Therapeutics has a 52-week low of $11.03 and a 52-week high of $32.95. The stock’s 50 day moving average price is $16.29.

Intellia Therapeutics (NASDAQ:NTLA) last posted its quarterly earnings data on Thursday, August 1st. The company reported ($0.56) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.61) by $0.05. The business had revenue of $11.10 million for the quarter, compared to the consensus estimate of $7.15 million. Intellia Therapeutics had a negative net margin of 257.28% and a negative return on equity of 31.68%. The company’s revenue was up 44.2% compared to the same quarter last year. During the same period last year, the firm posted ($0.52) earnings per share. Equities analysts expect that Intellia Therapeutics will post -2.4 EPS for the current year.

Several hedge funds and other institutional investors have recently bought and sold shares of NTLA. Nikko Asset Management Americas Inc. boosted its stake in shares of Intellia Therapeutics by 381.7% in the second quarter. Nikko Asset Management Americas Inc. now owns 5,161,098 shares of the company’s stock valued at $84,487,000 after purchasing an additional 4,089,744 shares during the period. ARK Investment Management LLC lifted its stake in Intellia Therapeutics by 17.3% in the first quarter. ARK Investment Management LLC now owns 7,981,198 shares of the company’s stock worth $136,319,000 after acquiring an additional 1,179,246 shares during the last quarter. Sumitomo Mitsui Trust Holdings Inc. raised its holdings in Intellia Therapeutics by 111.8% during the second quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 2,216,660 shares of the company’s stock worth $36,287,000 after purchasing an additional 1,169,968 shares in the last quarter. Deutsche Bank AG raised its holdings in Intellia Therapeutics by 75.5% during the fourth quarter. Deutsche Bank AG now owns 635,956 shares of the company’s stock worth $8,680,000 after purchasing an additional 273,501 shares in the last quarter. Finally, Dimensional Fund Advisors LP raised its holdings in Intellia Therapeutics by 502.6% during the fourth quarter. Dimensional Fund Advisors LP now owns 260,259 shares of the company’s stock worth $3,552,000 after purchasing an additional 217,071 shares in the last quarter. 74.47% of the stock is owned by institutional investors and hedge funds.

About Intellia Therapeutics

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of therapeutics utilizing a biological tool known as the CRISPR/Cas9 system. The company develops in vivo programs focused on liver diseases, including transthyretin amyloidosis, alpha-1 antitrypsin deficiency, and primary hyperoxaluria.

Recommended Story: Trading Penny Stocks

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Intellia Therapeutics (NASDAQ:NTLA)

Receive News & Ratings for Intellia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intellia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.